A multivalent vaccine composition, a method of producing the multivalent vaccine composition, and an apparatus containing the multivalent vaccine composition. The multivalent vaccine composition may include a mixture. The mixture may include Neisseria meningitides serogroups A, C, Y, and W-135 oligosaccharides conjugated to glycan-free carrier proteins. When administered, the multivalent vaccine composition may provide long-lasting immunity to humans of all age groups, including infants.

Methods of treatment of cancer are provided. In particular, methods of treatment of low-grade serous ovarian cancers by inhibiting signaling of an EGFR family member are provided.

The invention provides compositions and methods for treating cancers. The method comprises administering a PD-1 axis binding antagonist and an OX40 binding agonist.

The invention relates to a method for identifying immunoreactive peptides. According to said method, a sample of tumorous and corresponding healthy tissue is first provided, the tumor-specific expression profile is subsequently determined and antigenic peptides are isolated from the tumorous tissue and analyzed. The respective data that has been obtained is then matched and peptides are identified on the basis of said data.

Compared to an unadjuvanted vaccine, an adjuvanted influenza vaccine can reduce by almost a quarter the risk of hospitalization for respiratory illness (e.g. influenza and pneumonia) in elderly recipients. Thus the invention provides a method for immunizing an elderly subject by administering an adjuvanted influenza vaccine, whereby the subject's risk of hospitalization for respiratory illness (e.g. influenza and pneumonia) is reduced relative to an elderly subject who receives an unadjuvanted influenza vaccine.

The invention is directed to a vaccine comprising: i) coxsackie B virus CBV1 and CBV2, and ii) at least one coxsackie B virus selected from CBV3, CBV4, CBV5 and CBV6. The CBVs are present in the vaccine in inactivated form, in the form of a component of the virus or as an antibody against the virus. The vaccine is effective in preventing and treating type 1 diabetes. So is an anti-coxsackie B virus composition provided.

The invention provides peptides derived from a ubiquitous protein, and nucleic acids encoding such peptides. The invention extends to various uses of these peptides and nucleic acids, for example, as antigens for use in vaccines per se and in the generation of antibodies for use in therapeutic drugs for the prevention, amelioration or treatment of infections caused by sepsis-inducing bacteria. The invention particularly benefits immunocompromised hosts such as neonates, babies, children, women of fertile age, pregnant women, foetuses, the elderly and diabetics.

The present invention concerns methods and compositions for evoking protective immune responses against pathogen infection or cancer. In certain embodiments, the methods and compositions comprise a lymphangiogenesis inducer and an antigen.

Provided are various embodiments relating to anti-IL4R antibodies that bind to canine IL4R. In various embodiments, such anti-IL4R antibodies can be used in methods to treat IL4/IL13-induced conditions, such as atopic dermatitis, allergic dermatitis, pruritus, asthma, psoriasis, scleroderma and eczema, in companion animals, such as canines and felines. Also provided are various embodiments relating to variant IgG Fc polypeptides and variant light chain constant regions of companion animal species for the preparation of antibodies or bispecific antibodies.

Effective and economical compositions and methods are disclosed for the treatment, and prevention of diseases and disorders associated with inflammation and/or damage to the gastrointestinal tract, including environmental enteric dysfunction. Compositions are provided comprising a synergistic combination of colostrum, immune egg, and optionally one or more additional active agents.